IGC Pharma (IGC) Cash from Operations (2010 - 2025)
IGC Pharma (IGC) posted quarterly Cash from Operations of 2090000.0 for Q3 2025, down 109.84% year-over-year from 21241224.49 in Q3 2024, and down 48.54% quarter-over-quarter from 1407000.0 in Q2 2025.
IGC Pharma (IGC) Cash from Operations (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Cash from Operations for 16 consecutive years, with 2090000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Operations fell 109.84% year-over-year to 2090000.0; the TTM figure through Sep 2025 stood at 5544000.0 (down 14.05% YoY), while the FY2026 annual figure was 1223000.0, up 74.49% from the prior year.
- Cash from Operations slipped to 2090000.0 in Q3 2025 per IGC's latest filing, from 1407000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 526000.0 in Q1 2024 and bottomed at 2505000.0 in Q1 2021.
- Historically, Cash from Operations has averaged 1605526.32 across 5 years, with a median of 1618000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations jumped 65.33% — and 2025, when it tumbled 109.84%.
- IGC Pharma's Cash from Operations stood at 2422000.0 in 2021, then surged by 31.96% to 1648000.0 in 2022, then climbed by 3.7% to 1587000.0 in 2023, then gained by 17.01% to 1317000.0 in 2024, then tumbled by 58.69% to 2090000.0 in 2025.
- Business Quant data shows IGC's Cash from Operations at 2090000.0 in Q3 2025, 1407000.0 in Q2 2025, and 730000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.09 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Mar 31, 2025 | -730,000.00 |
| Mar 31, 2025 | -730,000.00 |
| Dec 31, 2024 | -1.32 Mn |
| Dec 31, 2024 | -1.32 Mn |
| Sep 30, 2024 | -996,000.00 |
| Sep 30, 2024 | -996,000.00 |
| Jun 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -1.75 Mn |
| Mar 31, 2024 | -526,000.00 |
| Mar 31, 2024 | -526,000.00 |
| Dec 31, 2023 | -1.59 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | -1.47 Mn |
| Jun 30, 2023 | -1.47 Mn |